ANNUAL REPORT 2021
LUNDBECK
ANNUAL REPORT 2021
= CONTENTS
17/111
FINANCIAL
PERFORMANCE
2021 PRODUCT PORTFOLIO
Our strategic brands are Abilify Maintena
(schizophrenia), BrintellixⓇ/Trintellix® (depression),
RexultiⓇ/RxultiⓇ (depression/schizophrenia) and
VyeptiⓇ (migraine prevention).
Our product portfolio also includes AzilectⓇ
(Parkinson's disease), CipralexⓇ/LexaproⓇ
(depression), EbixaⓇ (Alzheimer's disease),
NortheraⓇ (symptomatic neurogenic orthostatic
hypotension), OnfiⓇ (Lennox-Gastaut syndrome),
Sabril (epilepsy) and XenazineⓇ (chorea
associated with Huntington's disease) as well as
other mature products.
Read more on pages 30-31.
SALES PERFORMANCE
Revenue reached DKK 16,299 million in 2021 compared to DKK
17,672 million in 2020. The decline in sales is mainly a
consequence of generic erosion of NortheraⓇ. Excluding
NortheraⓇ, sales grew by 6% in local currencies. The strategic
brands (Abilify MaintenaⓇ, BrintellixⓇ/Trintellix®, RexultiⓇ/RxultiⓇ
and VyeptiⓇ) grew 18% in local currencies and reached DKK
9,287 million or 57% of total revenue.
EUROPE
Revenue reached DKK 3,499 million in 2021 compared to DKK
3,329 million in 2020. In general, Europe sees robust underlying
demand offsetting a continuous negative average price
development and continued generic erosion on the mature
product portfolio. The strategic brands increased by 14% in local
currencies and reached DKK 2,198 million or 63% of sales. The
largest markets in Europe are Spain, Italy, France, Switzerland
and Greece.
Europe constituted 22% of total revenue (excluding effects from
hedging and Other revenue), which is a small increase from last
year.
Abilify MaintenaⓇ is Lundbeck's largest product in the region.
Sales uptake of Abilify MaintenaⓇ is robust with revenue
reaching DKK 1,175 million. Abilify MaintenaⓇ is the second
most prescribed long-acting injectable treatment for patients
with schizophrenia in many markets. Spain, Italy and France are
the largest European markets for Abilify MaintenaⓇ.
BrintellixⓇ/TrintellixⓇ revenue grew 19% in local currencies
reaching DKK 998 million. BrintellixⓇ is Lundbeck's second
largest product in Europe and realized solid growth across many
markets. The solid growth in Europe has in some markets been
dampened by a negative impact from the COVID-19 pandemic.
RexultiⓇ/RxultiⓇ revenue reached DKK 25 million following a
growth of 39% in local currencies. The product was recently
launched in Italy, where it has a volume share of 0.6% by
October 2021*, and the Czech Republic, thereby adding to
growth. RexultiⓇ/RxultiⓇ is co-promoted with Otsuka in most
markets.
REVENUE - EUROPE
Growth
DKKm
2021
2020
Growth
in local
currencies
Abilify MaintenaⓇ
1,175
1,081
9%
9%
BrintellixⓇ/Trintellix®
998
837
19%
20%
RexultiⓇ/RxultiⓇ
Strategic brands
CipralexⓇ
25
18
39%
39%
2,298
1,936
14%
14%
Other pharmaceuticals
Total revenue
530
771
523 (1%) (2%)
3,499
870 (11%) (11%)
3,329
5%
5%
IQVIAView entire presentation